<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335504</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00837</org_study_id>
    <secondary_id>NCI-2009-00837</secondary_id>
    <secondary_id>CDR0000467755</secondary_id>
    <secondary_id>MAY03-1-03</secondary_id>
    <secondary_id>MAY03-1-03</secondary_id>
    <secondary_id>N01CN35000</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT00335504</nct_id>
  </id_info>
  <brief_title>Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia</brief_title>
  <official_title>Randomized, Phase II Trial of Atorvastatin, RAFTILOSE Synergy 1, and Sulindac Among Patients at Increased Risk for Sporadic Colorectal Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase II trial is studying atorvastatin calcium to see how well it works
      compared to oligofructose-enriched inulin, sulindac, or a placebo in preventing cancer in
      patients at increased risk of developing colorectal neoplasia. Chemoprevention is the use of
      certain drugs or substances to keep cancer from forming, growing, or coming back. The use of
      atorvastatin calcium, oligofructose-enriched inulin, or sulindac may stop cancer from forming
      in patients at increased risk of colorectal neoplasia. It is not yet known whether
      atorvastatin calcium, oligofructose-enriched inulin, or sulindac are more effective than a
      placebo in preventing cancer in patients at increased risk of developing colorectal
      neoplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. Percent change in number of rectal aberrant cryptic foci (ACF) as measured by
      magnification chromoendoscopy

      SECONDARY OBJECTIVES:

      I. Screening for possible phase III testing II. Effects on proliferation (Ki67 expression)
      and apoptosis (caspase-3 expression) as measured by biopsy samples obtained from
      normal-appearing rectal mucosa at baseline and after completion of study treatment III.
      Correlation of endoscopic features with histologic characteristics of rectal ACF IV.
      Observation of the natural history of rectal ACF in patients receiving placebo V. Adverse
      events VI. Utilization of a biospecimen repository archive

      OUTLINE: This is a multicenter, prospective, randomized, partially blinded,
      placebo-controlled study. Patients are stratified according to history of prior surgical
      resection of the colon (yes vs no) and number of rectal aberrant cryptic foci (ACF) (5-9 vs
      &gt;= 10). Patients are randomized to 1 of 4 treatment arms.

      ARM I: Patients receive oral atorvastatin calcium once daily.

      ARM II: Patients receive oral sulindac twice daily.

      ARM III (blinded arm): Patients receive oral oligofructose-enriched inulin (Raftilose Synergy
      1) twice daily.

      ARM IV (blinded arm): Patients receive an oral placebo twice daily.

      In all arms, treatment continues for 6 months in the absence of unacceptable toxicity.

      Tissue samples are collected at baseline and at the completion of study treatment. Tissue is
      examined by immunohistochemistry for proliferation (Ki67) and apoptosis (cleaved caspase-3).

      After completion of study treatment, patients are followed at approximately 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Number of Rectal Aberrant Cryptic Foci (ACF) as Measured by Magnification Chromoendoscopy</measure>
    <time_frame>6 months</time_frame>
    <description>At the Pre-Intervention Evaluation, rectal ACF will be classified with respect to ACF number, crypt number, crypt size, tissue plane, staining intensity, and (optional) lumen shape for each subject. At the Post- Intervention Evaluation, these same parameters will be recorded and incident vs prevalent rectal ACF status will also be recorded. Compare each non-placebo arms versus the placebo arm to screen the three active study agents for possible phase III testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects on Proliferation (Ki67 Expression).</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Tissue is examined by immunohistochemistry for Ki67. Measured by biopsy samples obtained from normal-appearing rectal mucosa at baseline and after completion of study treatment. Wilcoxon will be used to assess significant differences between the intervention arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Apoptosis (Caspase-3 Expression).</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Tissue is examined by immunohistochemistry for cleaved caspase-3. Measured by biopsy samples obtained from normal-appearing rectal mucosa at baseline and after completion of study treatment. Wilcoxon will be used to assess significant differences between the intervention arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events.</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with participation in a study, whether or not related to that participation. Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 3.0. Number of adverse events per grade level.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Precancerous Condition</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (atorvastatin calcium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral atorvastatin once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (sulindac)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sulindac twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (oligofructose-enriched inulin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive an oral placebo twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oligofructose-enriched inulin</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm III (oligofructose-enriched inulin)</arm_group_label>
    <other_name>Beneo Synergy 1</other_name>
    <other_name>Synergy 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulindac</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II (sulindac)</arm_group_label>
    <other_name>Aflodac</other_name>
    <other_name>Algocetil</other_name>
    <other_name>Clinoril</other_name>
    <other_name>SULIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm IV (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin calcium</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (atorvastatin calcium)</arm_group_label>
    <other_name>CI-981</other_name>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (atorvastatin calcium)</arm_group_label>
    <arm_group_label>Arm II (sulindac)</arm_group_label>
    <arm_group_label>Arm III (oligofructose-enriched inulin)</arm_group_label>
    <arm_group_label>Arm IV (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:

          -  ECOG performance status 0-2

          -  Platelet count &gt;= 100,000/mm^3

          -  Fertile patients must agree to use effective contraception

          -  No history of inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis)

          -  No invasive malignancy within the past 5 years except nonmelanoma skin cancer or
             colorectal cancer

          -  No history of endoscopically-confirmed peptic ulcer disease

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to the study agents

          -  No history of chronic liver disease or unexplained persistent elevations of serum
             transaminases

          -  No history of allergic-type reactions, including asthma or urticaria, to aspirin or
             NSAIDs

          -  No uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness or social situations that would preclude study compliance

          -  At least 6 weeks since prior oral corticosteroids

          -  Creatinine =&lt; 1.5 times ULN

          -  Creatine phosphokinase =&lt; 1.5 times ULN

          -  Not pregnant or nursing

          -  At least 6 weeks since prior statins

          -  At increased risk for developing sporadic colorectal neoplasia, as defined by 1 of the
             following:

               -  History of colon cancer (excluding stage IV or Dukes' D tumors)

               -  Must have completed prior adjuvant therapy for colon cancer &gt;= 12 months ago

          -  History of colorectal adenomas, meeting any of the following criteria:

               -  &gt;= 1 cm in diameter

               -  &gt;= 3 in total number

               -  Any component of villous morphology

               -  High-grade dysplasia

          -  At least 5 rectal aberrant cryptic foci (ACF), by magnification chromoendoscopy,
             meeting both of the following criteria:

               -  At least 5 aggregated crypts in a single grouping (maximum spacing between crypts
                  must be =&lt; 2 times the average crypt diameter)

               -  Crypt diameter &gt;= 1.5 times the diameter of surrounding normal crypts

          -  No history of rectal cancer, familial adenomatous polyposis, or hereditary
             nonpolyposis colorectal cancer

          -  Negative pregnancy test

          -  At least 6 months since prior and no concurrent regular use* of nonsteroidal
             anti-inflammatory drugs** (NSAIDs) or statins

          -  Concurrent aspirin at cardioprotective doses (=&lt; 162.5 mg/day or 325 mg every other
             day) allowed

          -  No prior rectal surgery involving mucosal resection

          -  No prior pelvic radiation therapy

          -  No concurrent regular use* of cyclooxygenase-2 inhibitors

          -  No concurrent anticoagulant drugs (i.e., warfarin, heparin, clopidogrel bisulfate, or
             extended-release dipyridamole)

          -  No concurrent use of any of the following:

               -  Fibrates (e.g., gemfibrozil or fenofibrate)

               -  Cyclosporine

               -  Erythromycin or macrolide antibiotics

               -  Protease inhibitors

               -  Azole antifungals

               -  Diltiazem

               -  Verapamil

               -  Compounds containing niacin or nicotinic acid

                    -  Defined as 7 consecutive days for &gt; 3 weeks OR &gt; 21 days total during study
                       participation

                    -  Patients may be eligible for study treatment after discontinuing NSAIDs for
                       12 weeks, at the discretion of their health care provider

          -  No other concurrent investigational agents

          -  No planned (or likely to require) clinically indicated colonoscopy or flexible
             sigmoidoscopy during study treatment

          -  Bilirubin =&lt; 1.5 times ULN

          -  Hemoglobin &gt;= lower limit of normal

          -  AST =&lt; 1.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase =&lt; 1.5 times ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Limburg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <results_first_submitted>November 26, 2012</results_first_submitted>
  <results_first_submitted_qc>January 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2013</results_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Sulindac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>142 subjects were pre-registered through 10 Cancer Prevention Network (CPN) member organizations from April 2006 to August 2008.</recruitment_details>
      <pre_assignment_details>57 subjects were excluded from the trial before assignment to groups: 13 did not have baseline Magnification chromoendoscopy (MCE), 33 had &lt; 5 rectal ACF, 8 did not meet eligibility criteria, and 3 were withdrawn.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Atorvastatin Calcium)</title>
          <description>Patients receive 20 mg tablet oral atorvastatin once daily.</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Sulindac)</title>
          <description>Patients receive 150 mg tablet oral sulindac twice daily.</description>
        </group>
        <group group_id="P3">
          <title>Arm III (Oligofructose-enriched Inulin)</title>
          <description>Patients receive 6gm powder oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.</description>
        </group>
        <group group_id="P4">
          <title>Arm IV (Placebo)</title>
          <description>Patients receive an oral placebo (maltodextrin powder) twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Atorvastatin Calcium)</title>
          <description>Patients receive 20 mg tablet oral atorvastatin once daily.</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Sulindac)</title>
          <description>Patients receive 150 mg tablet oral sulindac twice daily.</description>
        </group>
        <group group_id="B3">
          <title>Arm III (Oligofructose-enriched Inulin)</title>
          <description>Patients receive 6gm powder oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.</description>
        </group>
        <group group_id="B4">
          <title>Arm IV (Placebo)</title>
          <description>Patients receive an oral placebo (maltodextrin powder) twice daily.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="44" upper_limit="78"/>
                    <measurement group_id="B2" value="55" lower_limit="41" upper_limit="74"/>
                    <measurement group_id="B3" value="64" lower_limit="48" upper_limit="78"/>
                    <measurement group_id="B4" value="57" lower_limit="44" upper_limit="72"/>
                    <measurement group_id="B5" value="58" lower_limit="41" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Surgical Resection</title>
          <description>History of prior surgical resection of the colon: Yes vs. No</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Number of Rectal Aberrant Cryptic Foci (ACF) as Measured by Magnification Chromoendoscopy</title>
        <description>At the Pre-Intervention Evaluation, rectal ACF will be classified with respect to ACF number, crypt number, crypt size, tissue plane, staining intensity, and (optional) lumen shape for each subject. At the Post- Intervention Evaluation, these same parameters will be recorded and incident vs prevalent rectal ACF status will also be recorded. Compare each non-placebo arms versus the placebo arm to screen the three active study agents for possible phase III testing.</description>
        <time_frame>6 months</time_frame>
        <population>The population used for the analysis is patients having at least 5 rectal ACF and completing both the pre- and post-intervention MCE assessments and using intention to treat principles.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Atorvastatin Calcium)</title>
            <description>Patients receive 20 mg tablet oral atorvastatin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Sulindac)</title>
            <description>Patients receive 150 mg tablet oral sulindac twice daily.</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Oligofructose-enriched Inulin)</title>
            <description>Patients receive 6gm powder oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (Placebo)</title>
            <description>Patients receive an oral placebo (maltodextrin powder) twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Number of Rectal Aberrant Cryptic Foci (ACF) as Measured by Magnification Chromoendoscopy</title>
          <description>At the Pre-Intervention Evaluation, rectal ACF will be classified with respect to ACF number, crypt number, crypt size, tissue plane, staining intensity, and (optional) lumen shape for each subject. At the Post- Intervention Evaluation, these same parameters will be recorded and incident vs prevalent rectal ACF status will also be recorded. Compare each non-placebo arms versus the placebo arm to screen the three active study agents for possible phase III testing.</description>
          <population>The population used for the analysis is patients having at least 5 rectal ACF and completing both the pre- and post-intervention MCE assessments and using intention to treat principles.</population>
          <units>percent change in number of ACF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="49.1"/>
                    <measurement group_id="O2" value="-13.3" spread="55.4"/>
                    <measurement group_id="O3" value="-8.8" spread="49.2"/>
                    <measurement group_id="O4" value="-8.6" spread="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The study was designed to test the hypotheses of observing a 25% difference in % change ACF over baseline, between patients treated with atorvastatin compared to placebo. N=25 subjects per group yielded 93% power to detect this difference using a 2 sided t-test at significance level of 0.05. Non-parametric tests (eg, Wilcoxon Rank Sum) could be used if the statistical assumptions of the t-test were violated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <p_value_desc>Adjusting for multiple comparisons yields 84% power to detect a difference of at least 25% in % change of ACF at the 0.016 level of significance and using a two-sample, 2-sided t-test.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The study was designed to test the hypotheses of observing a 25% difference in % change ACF over baseline, between patients treated with sulindac compared to placebo. N=25 subjects per group yielded 93% power to detect this difference using a 2 sided t-test at significance level of 0.05. Non-parametric tests (eg, Wilcoxon Rank Sum) could be used if the statistical assumptions of the t-test were violated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <p_value_desc>Adjusting for multiple comparisons yields 84% power to detect a difference of at least 25% in % change of ACF at the 0.016 level of significance and using a two-sample, 2-sided t-test.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The study was designed to test the hypotheses of observing a 25% difference in % change ACF over baseline, between patients treated with oligofructose-enriched inulin compared to placebo. N=25 subjects per group yielded 93% power to detect this difference using a 2 sided t-test at significance level of 0.05. Non-parametric tests (eg, Wilcoxon Rank Sum) could be used if the statistical assumptions of the t-test were violated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <p_value_desc>Adjusting for multiple comparisons yields 84% power to detect a difference of at least 25% in % change of ACF at the 0.016 level of significance and using a two-sample, 2-sided t-test.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Signed Rank p-value for comparison of % change in ACF within each randomization arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Sign test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Signed Rank p-value for comparison of % change in ACF within each randomization arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Sign test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Signed Rank p-value for comparison of % change in ACF within each randomization arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Sign test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Signed Rank p-value for comparison of % change in ACF within each randomization arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Proliferation (Ki67 Expression).</title>
        <description>Tissue is examined by immunohistochemistry for Ki67. Measured by biopsy samples obtained from normal-appearing rectal mucosa at baseline and after completion of study treatment. Wilcoxon will be used to assess significant differences between the intervention arms.</description>
        <time_frame>Up to 6 months</time_frame>
        <population>Patients with assay data from baseline and post-intervention biopsy samples of normal-appearing rectal mucosa.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Atorvastatin Calcium)</title>
            <description>Patients receive 20 mg tablet oral atorvastatin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Sulindac)</title>
            <description>Patients receive 150 mg tablet oral sulindac twice daily.</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Oligofructose-enriched Inulin)</title>
            <description>Patients receive 6gm powder oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (Placebo)</title>
            <description>Patients receive an oral placebo (maltodextrin powder) twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Proliferation (Ki67 Expression).</title>
          <description>Tissue is examined by immunohistochemistry for Ki67. Measured by biopsy samples obtained from normal-appearing rectal mucosa at baseline and after completion of study treatment. Wilcoxon will be used to assess significant differences between the intervention arms.</description>
          <population>Patients with assay data from baseline and post-intervention biopsy samples of normal-appearing rectal mucosa.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="62.3"/>
                    <measurement group_id="O2" value="12.2" spread="52.8"/>
                    <measurement group_id="O3" value="34.7" spread="70.6"/>
                    <measurement group_id="O4" value="13.6" spread="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon Rank Sum p-value for comparison of % change in Ki67 between atorvastatin and placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon Rank Sum p-value for comparison of % change in Ki67 between sulindac and placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon Rank Sum p-value for comparison of % change in Ki67 between oligofructose-enriched inulin and placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Apoptosis (Caspase-3 Expression).</title>
        <description>Tissue is examined by immunohistochemistry for cleaved caspase-3. Measured by biopsy samples obtained from normal-appearing rectal mucosa at baseline and after completion of study treatment. Wilcoxon will be used to assess significant differences between the intervention arms.</description>
        <time_frame>Up to 6 months</time_frame>
        <population>Patients with assay data from baseline and post-intervention biopsy samples of normal-appearing rectal mucosa.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Atorvastatin Calcium)</title>
            <description>Patients receive 20 mg tablet oral atorvastatin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Sulindac)</title>
            <description>Patients receive 150 mg tablet oral sulindac twice daily.</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Oligofructose-enriched Inulin)</title>
            <description>Patients receive 6gm powder oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (Placebo)</title>
            <description>Patients receive an oral placebo (maltodextrin powder) twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Apoptosis (Caspase-3 Expression).</title>
          <description>Tissue is examined by immunohistochemistry for cleaved caspase-3. Measured by biopsy samples obtained from normal-appearing rectal mucosa at baseline and after completion of study treatment. Wilcoxon will be used to assess significant differences between the intervention arms.</description>
          <population>Patients with assay data from baseline and post-intervention biopsy samples of normal-appearing rectal mucosa.</population>
          <units>Percent change of caspase-3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.0" spread="140.3"/>
                    <measurement group_id="O2" value="131.9" spread="154.1"/>
                    <measurement group_id="O3" value="120.5" spread="195.6"/>
                    <measurement group_id="O4" value="130.6" spread="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon Rank Sum p-value for comparison of % change in apoptosis between atorvastatin calcium and placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon Rank Sum p-value for comparison of % change in apoptosis between sulindac and placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon Rank Sum p-value for comparison of % change in apoptosis between oligofructose-enriched inulin and placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events.</title>
        <description>Defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with participation in a study, whether or not related to that participation. Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 3.0. Number of adverse events per grade level.</description>
        <time_frame>Up to 30 days after completion of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Atorvastatin Calcium)</title>
            <description>Patients receive 20 mg tablet oral atorvastatin once daily.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Sulindac)</title>
            <description>Patients receive 150 mg tablet oral sulindac twice daily.</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Oligofructose-enriched Inulin)</title>
            <description>Patients receive 6gm powder oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (Placebo)</title>
            <description>Patients receive an oral placebo (maltodextrin powder) twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events.</title>
          <description>Defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with participation in a study, whether or not related to that participation. Graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 3.0. Number of adverse events per grade level.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Start of treatment to 30 days past the end of treatment.</time_frame>
      <desc>Common Toxicity Criteria for Adverse Events (CTCAE) v3</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Atorvastatin Calcium)</title>
          <description>Patients receive 20 mg tablet oral atorvastatin once daily.</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Sulindac)</title>
          <description>Patients receive 150 mg tablet oral sulindac twice daily.</description>
        </group>
        <group group_id="E3">
          <title>Arm III (Oligofructose-enriched Inulin)</title>
          <description>Patients receive 6gm powder oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.</description>
        </group>
        <group group_id="E4">
          <title>Arm IV (Placebo)</title>
          <description>Patients receive an oral placebo (maltodextrin powder) twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear - Other Specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine - Other Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other (Specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Muscle Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Variation in endpoint measurement across sites, relatively small sample size, and rectal biomarker assessments only may have contributed to challenges in full data interpretation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Paul Limburg</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-9093</phone>
      <email>limburg.paul@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

